AMGEN INC
AMGN · XNASCIK 318154fmd_02T53VP4T86EN7A5VXW3G0PZWNManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2007 to Sep 30, 2026, 75 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 22,991 | 22,849 | 23,747 | 23,362 | 25,424 | 25,979 | 26,323 | 28,190 | 33,424 | 36,751 |
| Cost of revenue | 4,162 | 4,069 | 4,101 | 4,356 | 6,159 | 6,454 | 6,406 | 8,451 | 12,858 | 12,037 |
| Gross profit | 18,829 | 18,780 | 19,646 | 19,006 | 19,265 | 19,525 | 19,917 | 19,739 | 20,566 | 24,714 |
| Research and development | 3,840 | 3,562 | 3,737 | 4,116 | 4,207 | 4,819 | 4,434 | 4,784 | 5,964 | 7,272 |
| Selling, general and administrative | 5,062 | 4,870 | 5,332 | 5,150 | 5,730 | 5,368 | 5,414 | 6,179 | 7,096 | 7,050 |
| Operating income | 9,794 | 9,973 | 10,263 | 9,674 | 9,139 | 7,639 | 9,566 | 7,897 | 7,258 | 9,080 |
| Interest expense | 1,260 | 1,304 | 1,392 | 1,289 | 1,262 | 1,197 | 1,406 | 2,875 | 3,155 | 2,755 |
| Interest and investment income | – | – | – | – | – | 11 | 127 | 1,200 | 510 | 408 |
| Other non-operating income (expense) | 629 | 928 | 674 | 753 | 256 | 259 | (814) | 2,833 | 506 | 2,651 |
| Income before taxes | 9,163 | 9,597 | 9,545 | 9,138 | 8,133 | 6,701 | 7,346 | 7,855 | 4,609 | 8,976 |
| Income tax expense | 1,441 | 7,618 | 1,151 | 1,296 | 869 | 808 | 794 | 1,138 | 519 | 1,265 |
| Net income from continuing operations | 7,722 | 1,979 | 8,394 | 7,842 | 7,264 | 5,893 | 6,552 | 6,717 | 4,090 | 7,711 |
| Net income | 7,722 | 1,979 | 8,394 | 7,842 | 7,264 | 5,893 | 6,552 | 6,717 | 4,090 | 7,711 |